Literature DB >> 16785774

Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression. A randomised, double-blind pilot study.

M P Søndergaard1, J O Jarden, K Martiny, G Andersen, P Bech.   

Abstract

BACKGROUND: Post-stroke depression affects the outcome of stroke rehabilitation and is observed in approximately 30% of all stroke patients. We investigated whether the addition of light treatment to medical antidepressants influences the course of depression as measured by the Hamilton Depression Scale.
METHODS: The effect of a combination of light therapy and citalopram in stroke victims receiving citalopram was examined by use of two different doses of light therapy under double-blind conditions. Altogether, 63 patients were included in the study. The mean age was 74.9 years.
RESULTS: After 4 weeks of therapy, the 6-item subscale of the Hamilton Depression Scale showed a statistically significantly larger improvement in patients receiving high-intensity light treatment compared to those treated with medium-intensity light (p < 0.05).
CONCLUSION: This pilot study demonstrates a dose response effect of light used as an adjunct therapy to antidepressants in post-stroke patients with major depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785774     DOI: 10.1159/000092895

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  3 in total

Review 1.  A Narrative Review on the Non-Pharmacologic Interventions in Post-Stroke Depression.

Authors:  Tissa Wijeratne; Carmela Sales; Chanith Wijeratne
Journal:  Psychol Res Behav Manag       Date:  2022-07-07

Review 2.  Antidepressant chronotherapeutics for bipolar depression.

Authors:  Francesco Benedetti
Journal:  Dialogues Clin Neurosci       Date:  2012-12       Impact factor: 5.986

3.  Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis.

Authors:  Jing Hu; Li Ma; Zeng-Ye Yang
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.